NR3C2 and chronic kidney disease: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, was approved for diabetic kidney disease based on the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease study.86 The placebo-controlled randomized study of participants with CKD receiving maximum tolerated doses of RAAS blockers showed significantly decreased risk of CKD progression in the finerenone group compared with placebo group but also higher rates of hyperkalemia.